S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.35%) $91.45

Aktualne aktualizacje dla Epigenomics AG [EPGNY]

Giełda: OTC Sektor: Healthcare Branża: Diagnostics & Research
Ostatnio aktualizowano21 rugs. 2022 @ 21:34

0.00% $ 2.39

Live Chart Being Loaded With Signals

Commentary (21 rugs. 2022 @ 21:34):

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China...

Stats
Dzisiejszy wolumen 212.00
Średni wolumen 9.00
Kapitalizacja rynkowa 0.00
Last Dividend $0.0297 ( 2021-09-16 )
Next Dividend $0 ( N/A )
P/E -1.604
ATR14 $0 (0.00%)

Epigenomics AG Korelacja

10 Najbardziej pozytywne korelacje
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Epigenomics AG Finanse

Annual 2021
Przychody: $6.20M
Zysk brutto: $6.07M (97.81 %)
EPS: $-0.271
FY 2021
Przychody: $6.20M
Zysk brutto: $6.07M (97.81 %)
EPS: $-0.271
FY 2020
Przychody: $842 000
Zysk brutto: $697 000 (82.78 %)
EPS: $-2.48
FY 2019
Przychody: $1.13M
Zysk brutto: $872 000 (77.51 %)
EPS: $-4.48

Financial Reports:

No articles found.

Epigenomics AG Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Epigenomics AG Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.458 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $0.833 2018-10-31
Last Dividend $0.0297 2021-09-16
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 5 --
Total Paid Out $2.72 --
Avg. Dividend % Per Year 0.00% --
Score 0.55 --
Div. Sustainability Score 0.458
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-09-23)
$0 Estimate 0.00 %
Dividend Stability
0.05 Very Bad
Dividend Score
0.55
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
RTMVY Ex Dividend Knight 2023-09-28 Annually 0 0.00%
FABP Ex Dividend Knight 2023-07-31 Quarterly 0 0.00%
YARIY Ex Dividend Junior 2023-06-13 Annually 0 0.00%
LTOUF Ex Dividend Junior 2023-08-01 Annually 0 0.00%
CGXYY Ex Dividend Junior 2023-07-11 Annually 0 0.00%
SOMC Ex Dividend Knight 2023-07-13 Quarterly 0 0.00%
GLAPY Ex Dividend Knight 2023-08-25 Semi-Annually 0 0.00%
ACCYY Ex Dividend Knight 2023-05-23 Sporadic 0 0.00%
NEFB Ex Dividend Junior 2023-06-29 Semi-Annually 0 0.00%
CNND Ex Dividend Junior 2023-07-27 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-0.3911.500-7.83-10.00[0 - 0.5]
returnOnAssetsTTM-0.09841.200-3.28-3.94[0 - 0.3]
returnOnEquityTTM-0.1871.500-3.19-4.78[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM11.060.80010.008.00[1 - 3]
quickRatioTTM10.720.80010.008.00[0.8 - 2.5]
cashRatioTTM10.721.50010.0010.00[0.2 - 2]
debtRatioTTM0.0187-1.5009.69-10.00[0 - 0.6]
interestCoverageTTM-45.351.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-0.4632.00-0.154-0.309[0 - 30]
freeCashFlowPerShareTTM-0.4672.00-0.233-0.467[0 - 20]
debtEquityRatioTTM0.0208-1.5009.92-10.00[0 - 2.5]
grossProfitMarginTTM0.9781.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-0.3801.000-9.60-9.60[0.1 - 0.6]
cashFlowToDebtRatioTTM-9.031.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.2520.800-1.657-1.325[0.5 - 2]
Total Score0.458

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-8.201.000-0.9290[1 - 100]
returnOnEquityTTM-0.1872.50-2.05-4.78[0.1 - 1.5]
freeCashFlowPerShareTTM-0.4672.00-0.156-0.467[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.4632.00-0.154-0.309[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.4631.500-6.420[0.5 - 2]
operatingCashFlowSalesRatioTTM-0.6691.000-10.000[0.1 - 0.5]
Total Score-2.63

Epigenomics AG

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej